Press Release For Immediate Release

Glenmark Generics receives approval from the USFDA for Lithium Carbonate extended-release tablets

December 28, 2010: Glenmark Generics Inc., USA(GGI) , the United States subsidiary of Glenmark Generics Ltd, today announced that they have been granted final Abbreviated New Drug Application (ANDA) approval by the United States Food and Drug Administration (U.S. FDA) for Lithium Carbonate 300 mg extended-release tablets. GGI will commence marketing and distribution of the product immediately.

Lithium Carbonate 300mg extended-release tablets are Glenmark's generic version of Noven Therapeutics Lithobid® which is indicated in the treatment of manic episodes of bipolar disorder. Total sales achieved in the United States for the 12 month period ending September 2010 were USD 21 million, according to IMS Health. Glenmark anticipates a successful launch as they will be one of two generic players in this market.

Glenmark is currently authorized to distribute 66 products in the United States. The Company maintains an aggressive ANDA filing strategy and continues to rely on the strength of its internal pipeline projects as well as continuing to explore partnerships to augment the breadth of their existing portfolio.

About Glenmark Generics limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader.

GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza
Glenmark, Mumbai, India Tel: [+91 22] 40189919
Email : connect@glenmark-generics.com